IsoRay Announces Record Seed Orders And Resulting Impact On Cash Reserves, New Debt Financing, And Planned Reduction In Outstanding Shares

RICHLAND, Wash.--(BUSINESS WIRE)--June 20, 2006--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY - News), a medical technology company focusing on innovative treatment for prostate and other soft tissue cancer tumors through use of its proprietary Cesium-131, announced a dramatic increase in seed orders for the quarter ending June 30, 2006.